Extra chemotherapy after surgery for colorectal cancer with positive ctDNA
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving more chemotherapy can help people who still have cancer DNA in their blood after surgery and standard chemotherapy for colorectal cancer. The goal is to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove stage III or high-risk stage II colorectal cancer, and finished a standard chemotherapy (FOLFOX or CAPOX) 3 to 6 months ago.
- A blood test after chemotherapy found tiny bits of cancer DNA (ctDNA) still present in your body.
- You are between 18 and 80 years old. If you are 70 or older, you must pass a quick health questionnaire (G8 score > 14).
- You are generally able to take care of yourself and are not in bed or needing help more than half the day.
- Your blood counts and liver/kidney function are within safe ranges (your doctor will check these).
- You have not taken the specific chemotherapy drugs trifluridine/tipiracil or irinotecan in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test that looks at cancer DNA can help decide whether you need “adjuvant” (extra) chemotherapy after colon cancer surgery. It may help some patients avoid unnecessary chemotherapy while still keeping the cancer from coming back.
This trial checks whether a special blood test (ctDNA methylation) can help decide the best chemotherapy after surgery for people at higher risk of colon cancer coming back. It may help spare some patients unnecessary treatment while aiming to improve outcomes for those likely to relapse.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This study tests whether a special blood test (looking for cancer DNA) can help doctors decide if you need chemotherapy after colorectal cancer surgery. The goal is to avoid unnecessary chemotherapy while making sure patients who need it get treated.
This trial studies how to find tiny hidden cancer cells after stage III colon cancer surgery using a blood test. If the blood test shows tumor DNA, you may get additional treatment to lower the chance of cancer coming back.
Hear when a new Colon or Upper Rectum Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.